- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Y-mAbs Therapeutics (NASDAQ:YMAB), Quotes and News Summary
Y-mAbs Therapeutics (NASDAQ: YMAB)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-04 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.720 | -0.640 | 0.0800 | ||||
| REV | 10.900M | 10.486M | -414.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Y-mAbs Therapeutics Questions & Answers
You can purchase shares of Y-mAbs Therapeutics (NASDAQ: YMAB) through any online brokerage.
Other companies in Y-mAbs Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), Sangamo Therapeutics (NASDAQ:SGMO), TG Therapeutics (NASDAQ:TGTX), PMV Pharma (NASDAQ:PMVP) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by BMO Capital on Friday, June 24, 2022. The analyst firm set a price target for 27.00 expecting YMAB to rise to within 12 months (a possible 76.01% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $15.34 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Y-mAbs Therapeutics.
Y-mAbs Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Y-mAbs Therapeutics.
Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.